Demographic and Socioeconomic Predictors of GDMT Optimization: An Observational Analysis 
 
 
Presenter: Stanton Greenstone.

Real-world optimisation of guideline-directed medical therapy (GDMT) in heart failure with reduced ejection fraction (HFrEF) remains limited, and reports of comparable or higher GDMT rates among Black patients despite worse outcomes are incompletely understood. This retrospective cohort study across 23 University of Chicago Medicine primary care clinics (2018-2025) examined predictors of GDMT optimisation, defined as prescription of all four main classes. Among 774 patients (69% Black; 24% in the top Area Deprivation Index [ADI] quintile), Black patients had higher GDMT optimisation (47% vs 35%, p<0.01) and prior HF hospitalisation (45% vs 34%, p<0.01) than White patients. Black race was associated with higher optimisation (odds ratio [OR] 1.57, 95% confidence interval [CI] 1.1-2.3, p = 0.018), attenuating with comorbidity adjustment, while high ADI was associated with lower optimisation (OR 0.61, 95% CI 0.4-0.9, p = 0.017). Prior HF admission mediated approximately 22% of the race-GDMT association. Hospitalisation thus helps explain higher optimisation among Black patients, potentially supporting proactive outpatient prescribing, while social deprivation is an independent barrier.

Kidney Failure Risk Equation, Clinical Outcomes, and Effect of Finerenone in HFmrEF/HFpEF: Insights from FINEARTS-HF

Presenter: Ryohei Ono.

The Kidney Failure Risk Equation (KFRE) is guideline recommended for estimating kidney failure risk in chronic kidney disease (CKD), but its prognostic relevance in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) had not been described. In FINEARTS-HF, a trial of finerenone versus placebo, investigators related baseline 5-year KFRE scores to kidney and cardiovascular (CV) outcomes in 2,785 patients with an estimated glomerular filtration rate below 60 mL/min/1.73m². Compared with the lowest tertile, the highest tertile carried hazard ratios (95% confidence intervals) of 2.68 (1.56-4.61) for the kidney outcome and 2.10 (1.74-2.52) for first heart failure (HF) event or CV death. As a continuous variable, higher scores were associated with a steep rise in kidney risk and a less steep, linear rise in risk of first HF event or CV death. Finerenone reduced the primary outcome irrespective of baseline KFRE score (P-interaction=0.82). The KFRE may therefore provide prognostic information beyond kidney failure prediction in HFmrEF/HFpEF.

Finerenone and Real-World Hyperkalemia Rates in Individuals with Triple Comorbidities-Heart Failure, Chronic Kidney Disease, and Type 2 Diabetes

Presenter: Zihe Zheng.

Patients with concomitant heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes (T2D) face the highest risk of adverse outcomes but often miss guideline-directed medical therapy (GDMT) owing to fears of hyperkalemia (HK), and real-world HK data for finerenone in this group are limited. This retrospective cohort study used the Truveta U.S. electronic health record database (July 2021 to June 2025) to examine HK in 3,363 finerenone users with all three conditions over a median follow-up of 10.6 months; 20.5% had an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m². Serum potassium >5.5 mEq/L occurred in 409 patients (12.2%; 12.3/100 person-years) and ≥6.0 mEq/L in 206 (6.1%; 5.8/100 person-years). Rates were higher with baseline eGFR <30, prior HK, potassium binder use and HF diagnosed within 12 months before finerenone initiation. The authors consider HK incidence and severity manageable, supporting finerenone's real-world safety and suggesting that GDMT benefits likely outweigh perceived risks in such high-risk populations.

Finerenone versus Spironolactone in SGLT2 Inhibitor-Treated Patients with HFpEF: A Propensity-Matched Analysis

Presenter: Mohamad Fael.

The optimal mineralocorticoid receptor antagonist (MRA) for patients with heart failure with preserved ejection fraction (HFpEF) receiving sodium-glucose cotransporter-2 (SGLT2) inhibitors is uncertain, with limited real-world comparison of finerenone and spironolactone. In this TriNetX cohort, SGLT2 inhibitor-treated adults with HFpEF were grouped by finerenone or spironolactone use; after 1:1 propensity matching, 1,519 patients remained per cohort. At 1 year, finerenone was associated with lower hospitalisation (29.4% vs 40.8%; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.65-0.82), acute heart failure events (17.2% vs 26.4%; HR 0.67), acute kidney injury (23.0% vs 29.7%; HR 0.83), myocardial infarction (6.9% vs 10.8%; HR 0.70) and all-cause mortality (5.2% vs 10.6%; HR 0.55, 95% CI 0.42-0.72). Hyperkalemia and syncope rates were similar between groups. These associations favouring finerenone support prospective comparative studies to define the optimal MRA strategy in contemporary HFpEF management.

Preserved or Mildly Reduced Ejection Fraction: A Propensity Score Matched Analysis

Presenter: Muhammad Omar Akram.

Therapeutic options for heart failure with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) remain limited, and the effectiveness of spironolactone when left ventricular ejection fraction (LVEF) exceeds 40% is uncertain. Using TriNetX, investigators compared adults with HFpEF/HFmrEF by spironolactone use after heart failure diagnosis. Of 110,193 eligible patients, 16,584 (15.0%) received spironolactone, and 15,077 per cohort were analysed after propensity score matching. Spironolactone was associated with lower all-cause mortality at 1 year (risk ratio [RR] 0.86, 95% confidence interval [CI] 0.82-0.91; p<0.001) and 3 years (RR 0.85, 95% CI 0.82-0.88; p<0.001), and with fewer hospitalisations or emergency department visits, acute heart failure exacerbations and renal replacement therapy (all p<0.001). Acute kidney injury was more frequent with spironolactone (p<0.001), while atrial fibrillation and genitourinary adverse events were similar. The authors suggest spironolactone may improve outcomes in HFpEF and HFmrEF, warranting confirmation in adequately powered randomised controlled trials.

Neprilysin Inhibition After Afterload Relief: ARNI versus ACE Inhibitors/ARBs in HFrEF Following Transcatheter Aortic Valve Replacement

Presenter: Amer Kamal.

Angiotensin receptor-neprilysin inhibition (ARNI) is foundational in heart failure with reduced ejection fraction (HFrEF), but its benefit may be partly tied to neurohormonal activation under chronic pressure overload, so whether it retains an advantage over angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) after transcatheter aortic valve replacement (TAVR) is unclear. In a federated electronic health record network, adults with systolic HF who started ARNI or ACEi/ARB within 3 months of TAVR were compared. ARNI recipients (n=630) were markedly sicker than ACEi/ARB recipients (n=1,455). After propensity matching (499 per arm), 1-year acute HF events (9.0% vs 8.4%; hazard ratio [HR] 1.15, 95% confidence interval [CI] 0.68-1.96; p=0.60), all-cause mortality (7.0% vs 7.0%) and major adverse cardiovascular events (9.6% vs 11.0%) were comparable, and the primary estimate was unchanged after additional matching on severity markers. As residual confounding may have favoured the comparator, a modest ARNI benefit cannot be excluded; the incremental value of ARNI after TAVR remains uncertain and warrants prospective evaluation.

Predictors of Guideline-Directed Medical Therapy Uptake Among Rural-Residing Patients with Heart Failure

Presenter: Anand Jain.

Rural patients experience poor outcomes owing to limited access to cardiovascular care, with significant gaps in guideline-directed medical therapy (GDMT) for heart failure (HF), yet predictors of GDMT uptake in this population are poorly characterised. This prospective virtual registry included 661 patients hospitalised with acute HF at 13 rural hospitals receiving telemedicine-based cardiovascular care: 340 (51%) with HF with reduced ejection fraction (HFrEF; EF <50%) and 321 (49%) with HF with preserved ejection fraction (HFpEF; EF ≥50%). Quadruple therapy (HFrEF) and triple therapy (HFpEF) at any dose were prescribed at discharge in 17% and 4.7%, and at optimal dose in just 4.2% and 4.1%, respectively. Older age independently predicted lower uptake in both groups (per year, odds ratio [OR] 0.97). In HFrEF, chronic kidney disease predicted lower (OR 0.46; 95% confidence interval [CI] 0.30-0.68) and prior HF diagnosis higher (OR 1.58; 95% CI 1.16-2.17) prescription of quadruple therapy, while dual-eligible/Medicaid coverage predicted lower triple therapy in HFpEF (OR 0.65; 95% CI 0.41-0.99). GDMT uptake was low, and the authors call for strategies to improve in-hospital initiation and intensification.

Quadruple GDMT Reduces 30-Day Heart Failure Readmission in Real-World: SGLT2i Underutilisation Drives the Implementation Gap

Presenter: Darsh Patel.

US community discharge prescribing of quadruple guideline-directed medical therapy (GDMT) is poorly characterised, and patients with chronic kidney disease (CKD), who stand to benefit most from sodium-glucose cotransporter-2 inhibitors (SGLT2i), often receive them less frequently. This retrospective analysis of 168 consecutive heart failure admissions at a Philadelphia-area teaching hospital (2024-2025), including 75 (45%) with CKD, examined discharge GDMT and 30-day all-cause readmission. Quadruple therapy was prescribed in only 13.1%, below European registry benchmarks (44-66%). Thirty-day readmission was 31.8% with quadruple therapy versus 56.2% with incomplete GDMT (absolute risk reduction 24.3%, number needed to treat 4.1, relative risk reduction 43%). SGLT2i prescription was 17.3% in CKD versus 49.5% without CKD (p<0.0001), while diabetes did not influence prescribing (p=0.47). Quadruple GDMT was associated with lower readmission, although confounding by indication means causality cannot be established; targeting SGLT2i initiation in CKD represents a high-yield opportunity requiring larger prospective studies.

American Heart Association (AHA) Scientific Sessions 2026, November 6–9, Chicago, Illinois







Other Conference Highlights